MSHP 2013 Annual Conference
April 25-26, 2013
Mayo Civic Center
“Rounding the Bases for Safe and Healthy Patients”
Agenda/Speakers/CE Hours/ACPE Numbers/Objectives
Thursday, April 25th
Time
Total
Hours
8:00 – 9:30
1.5 hr.
Speaker/Presentation Title
Christopher Jerry, “The Emily Jerry Story from Tragedy to Triumph”
0134-0000-13-058-L05-P; 0134-0000-13-058-L05-T
Pharmacist Learning Objectives:
1. Discuss the events surrounding the medical error that resulted in Emily Jerry’s
death and a criminal prosecution.
2. Describe the “lessons learned” from Emily’s tragic death.
3. Describe ISMP recommended “safe practices that upon implementation will
immediately help reduce the probability of these types of medication errors
from occurring.
4. Identify and discuss the qualities of a safety culture that enhance harm
prevention.
Technician Objectives:
1. Discuss the events surrounding the medical error that resulted in Emily Jerry’s
death and a criminal prosecution.
2. Describe the “lessons learned” from Emily’s tragic death as they apply to the
pharmacy technician compounding error that occurred.
3. Describe ISMP recommended “safe practices that upon implementation will
immediately help reduce the probability of these types of medication errors
from occurring.
4. Identify and discuss the qualities of a safety culture that enhance harm
prevention.
10:00 – 11:00 1 hr.
Kay Perrotta, PharmD, MBA, BCPS - “Insights into Diagnosis and Treatment of
Angioedemia Hereditary and Other Types”
0134-0000-13-059-L01-P; 0134-0000-13-059-L01-T
Pharmacist Learning Objectives:
1. Describe the different types of angioedema.
2. Define the differences in etiology of the different types of angioedema.
3. Identify the effective treatments for allergic, idiopathic and hereditary
angioedema.
4. Explain how and why the newer agents work in patients with hereditary
angioedema.
5. Dispute the use of the newer C1 esterase inhibitors in the use of allergic
angioedema with symptoms of urticaria.
Technician Program Learning Objectives:
1.
2.
3.
4.
Describe the different types of angioedema.
Define the differences in etiology of the different types of angioedema.
Challenge the use of C1 esterase inhibitors in all types of angioedema.
Identify the disadvantages of using C1 esterase for non-hereditary angioedema
patients.
1
Thursday, April 25th (Continued)
Time
Total
Hours
10:00 – 11:00 1 hr.
Speaker/Presentation Title
Rebecca Fahrenbruch, PharmD, BCOP & Jeremy Whalen, PharmD, BCOP
“Oncology Medication Update”
0134-0000-13-060-L01-P; 0134-0000-13-060-L01-T
Pharmacist Learning Objectives:
1. Review new oncology medication and their indication of use
2. Discuss potential toxicities and monitoring recommendations for the new
oncology agents
3. Review Chronic Myelogenous Leukemia (CML)
4. Compare and contrast new Chronic Myelogenous Leukemia (CML) agents
5. Describe compounding practice of these agents
6. Inform regarding cost information and dosage forms of these agents
Technician Program Learning Objectives:
1. Identify mechanism of action and indication for newly approved oncology
medications
2. Discuss potential toxicities and monitoring recommendations for the new
oncology agents
3. Describe compounding practice of these agents
4. Inform regarding cost information and dosage forms of these agents
10:00 – 11:00 1 hr
Cody Wiberg, PharmD, M.S., R.Ph. – “Pharmacy Laws: Hot Topics”
0134-0000-13-061-L03-P; 0134-0000-13-061-L03-T
Pharmacist Learning Objectives:
1. Describe pending state and federal legislation that, if enacted, will have an
impact on the profession of pharmacy and the distribution of drugs
2. Define current laws and rules related to compounding and manufacturing
3. List issues that are likely to be the subject of new rules or statutes within the
next two years.
4. Identify recently implemented rule changes involving the registration of
pharmacy technicians.
Technician Program Learning Objectives:
1. Describe pending state and federal legislation that, if enacted, will have an
impact on the profession of pharmacy and the distribution of drugs
2. Define current laws and rules related to compounding and manufacturing,
including the roles that technicians may have in compounding
3. List issues that are likely to be the subject of new rules or statutes within the
next two years.
4. Identify the impact that recently implemented rule changes will have on initial
and renewal registrations of pharmacy technicians.
11:00 – 12:30 1.5 hr.
“Pearls
– Session I”
0134-0000-13-062-L01-P; 0134-0000-13-062-L01-T
Kathryn Schultz, PharmD, FASHP - “Interns Call the Shots at Bethesda Hospital”
Pharmacist Objectives:
1. Discuss the role of pharmacy interns in a health care worker immunization
campaign at one Minnesota hospital
Technician Objectives:
1. Discuss the role of pharmacy interns in a health care worker immunization
campaign at one Minnesota hospital.
2
Thursday, April 25th (Continued)
Time
Total
Hours
11:00 – 12:30 1.5 hr.
Speaker/Presentation Title
Katherine Miller, PharmD – “Implementation of a Clinical Scoring Tool to Assist
with Patient Prioritization”
Pharmacist Objectives:
1. Implementation of a clinical scoring tool has provided an opportunity for
pharmacists to prioritize their patients based on specific clinical
characteristics. T or F (Answer: True)
Technician Objectives:
1. Implementation of a clinical scoring tool has provided an opportunity for
pharmacists to prioritize their patients based on specific clinical characteristics.
T or F (Answer: True)
Rebecca Fahrenbruch, PharmD, BCOP – “Pegfilgrastim (Neulasta) Bone Pain:
Prevention with Loratadine or Dose Reduction”
Pharmacist Objectives:
1. Discuss the proposed mechanism and dosing of Loratadine used to prevent
bone pain and the recent data to support avoiding dose reduction of
Pegfilgrastim for bone pain.
Technician Objectives:
1. Discuss the proposed mechanism and dosing of Loratadine used to prevent
bone pain and the recent data to support avoiding dose reduction of
Pegfilgrastim for bone pain
Kristen McCullough, PharmD, BCPS, BOP – “Old Men, New Tricks: Advances in
Docetaxel-Refractory Prostate Cancer”
Pharmacist Objectives:
1. Describe the mechanism of action of cabazitaxel, abiraterone, and
enzalutamide
2. Compare and contrast expected outcomes of response and toxicity to each
agent
3. Outline appropriate patient counseling points for each agent
4. Apply clinical data to justify selection of therapy in docetaxel-refractory
prostate cancer
Technician Objectives:
1. Define castration-resistant prostate cancer as it applies to docetaxel failure
2. Describe the primary adverse drug reaction to cabazitaxel, abiraterone and
enzalutamide
3. Identify two unique preparation requirements for cabazitaxel
Amber Alstadt, PharmD, – “Acute Pain Management in Patients Taking Opioid
Antagonists”
Pharmacist Objectives:
1. Describe the pharmacokinetic and pharmacodynamic properties of opioid
antagonists.
2. Identify when to stop and restart opioid antagonist therapy when opioids may
be needed perioperatively.
3. Compare and contrast opioid alternatives for acute pain management in
patients taking opioid antagonists.
4. Construct a systematic approach to designing a patient-specific pain
management plan for patients taking opioid antagonists.
3
Thursday, April 25th (Continued)
Time
Total
Hours
11:00 – 12:30 1.5 hr.
Speaker/Presentation Title
Amber Alstadt, (Continued)
Technician Objectives:
1. Identify the name and dosage of available opioid antagonists.
2. Describe why opioids will not be effective for pain management in patients
taking opioid antagonists.
3. Identify the name and dosage ranges of opioid alternative pain medications.
4. Identify when to stop and restart opioid antagonist therapy when opioids may
be needed perioperatively.
Erin Frazee, PharmD, BCPS – “Dexmedetomidine: Is it the next thing on tap for alcohol
withdrawal?”
Pharmacist Objectives:
1. Contrast the pharmacologic mechanism of action and adverse effects of
benzodiazepines and dexmedetomidine as they pertain to use in alcohol
withdrawl
2. Evaluate the scientific caliber of existing literature for dexmedetomidine in
alcohol withdrawl syndrome
3. Identify the place in therapy for dexmedetomidine for alcohol withdrawl
syndrome
Technician Objectives:
1. List at least three symptoms associated with alcohol withdrawl
2. Explain one possible risk/adverse effect of rapidly escalating benzodiazepine
(i.e. lorazepam, midazolam) doses in the context of alcohol withdrawl
treatment.
3. Identify whether or not dexmedetomidine is appropriate for all patients with
alcohol withdrawl syndrome
Rebecca Palermo, PharmD, BCPS – “Pharmacoligic Approach to Beta-Blocker Overdose”
Pharmacist Objectives:
1. Define the pharmacology of the beta1-adrenergic receptor
2. Outline beta-blocker characteristics which help guide pharmacologic
management
3. Compare and contrast the options for pharmacologic management of betablocker overdose
4. Discuss the use and dosing of high dose insulin and dextrose for management
of beta-blocker overdose
Technician Objectives:
1. Outline the adverse effects and possible outcomes of beta-blocker overdose
2. Describe the options for pharmacologic management of beta-blocker overdose
3. Discuss the importance of stat preparation and administration of pharmacologic
agents for management of beta-blocker overdose
11:00 – 12:30
1.5 hr.
Gary Carlson, B.S. Pharm. – “NECC Meningitis Outbreak and Its Sequalla”
0134-0000-13-063-L04-P; 0134-0000-13-063-L04-T
Pharmacist Objectives:
1. Describe the NECC meningitis outbreak and its sequella.
2. Describe the known causes of the outbreak
3. Apply current Minnesota and Federal Law to sterile compounding.
4. Explain proposed changes at the Federal and State level.
5. Describe the probable impact on Health System pharmacy
4
Thursday, April 25th (Continued)
Time
11:00 – 12:30
Total
Hours
1.5 hr.
Speaker/Presentation Title
Gary Carlson, (Continued)
Technician Objectives:
1. Describe the NECC meningitis outbreak and its sequella
2. Describe the known causes of the outbreak
3. Apply current Minnesota and Federal Law to sterile compounding.
4. Explain proposed changes at the Federal and State level.
5. Describe the probable impact on Health System pharmacy
14:00 – 15:00
1hr.
“PPMI Roundtable”
Moderator:
Lance Oyen, PharmD, BCPS, FCCP, FCCM
Roundtable Panel:
Krista Huot, PharmD (MSHP-Arrowhead)
Paul Glynn, PharmD, BCPS, CGP (MSHP-Central)
Jan Puttbrese, PharmD, (MSHP-Heartland & Northwestern)
Gary Sigmeth, BS (MSHP-Southern)
0134-0000-13-064-L04-P; 0134-0000-13-064-L04-T
Pharmacist Objectives:
1. Highlight PPMI recommendations incorporated into pharmacy workflow at
various practice settings.
2. To deliver key practice model solutions from many practice settings to
audience.
3. To offer panelists from a variety of practices for audience questions and
answers
4. To discuss barriers and experiences in implementing practices or models
Technician Objectives:
1. Highlight PPMI recommendations incorporated into pharmacy workflow at
various practice settings.
2. To deliver key practice model solutions from many practice settings to
audience.
3. To offer panelists from a variety of practices for audience questions and
answers
4. To discuss barriers and experiences in implementing practices or models
15:30-16:30
1 hr.
Ben Anderson, PharmD, MPH – “Review of Meaningful Use Stage I and II Initiatives”
0134-0000-13-065-L04-P; 0134-0000-13-065-L04-T
Pharmacist Objectives:
1. Interpret the requirements for patient engagement, quality measures, health
information exchange, standards and Electronic Health Record (EHR) usability
for Meaningful Use Stage I
2. Differentiate Meaningful Use Stage II requirement changes from Stage I
requirements
3. Describe the role of pharmacy informatics in conformance with the Meaningful
Use standards
4. Distinguish the role of Clinical quality measures with the framework of
Meaningful Use
Technician Objectives:
1. Interpret the definition of Meaningful Use as it relates to a certified EHR
2. Explain the differences between Core Criteria and Menu Set Criteria
3. Describe the role of pharmacy technician as it relates to meeting Clinical
Quality Measures.
5
Thursday, April 25th (Continued)
Time
Total
Hours
15:30-16:30
No Credit
“Student Speed Networking Session”
Matt Kresl, PharmD, BCPS & Paul Wittmer, RPh, BS, MBA
15:30-16:30
1 hr.
“Pearls – Session II”
Speaker/Presentation Title
0134-0000-13-066-L01-P; 0134-0000-13-066-L01-T
Melissa Carlson, PharmD, BCPS – “Adverse Drug Event Tracking: Implementation of an
Electronic Trigger Notification Process in the EMR”
Pharmacist Objectives:
1. Describe the implementation of a new, electronic process for trigger
identification, patient chart review, and documentation.
Technician Objectives:
1. Describe the implementation of a new, electronic process for trigger
identification, patient chart review, and documentation.
Kati Shihadeh, PharmD, – “Required Indications for Antimicrobials”
Pharmacist Objectives:
1. To identify benefits of capturing required indications for antimicrobials during
physician order entry.
Technician Objectives:
1. To identify benefits of capturing required indications for antimicrobials during
physician order entry.
Emily Herstine, PharmD – “Appropriate Treatment for Candida glabrata”
Pharmacist Objectives:
1. Identify appropriate empiric therapy for Candida glabrata.
2. Describe current resistance patterns of Candida glabrata.
3. Describe appropriate step-down therapy for Candida glabrata.
Technician Objectives:
1. Differentiate echinocandin antifungals from azole antifungals.
Natasha Thoner, PharmD – “Intrapartum Antiretroviral Therapy”
Pharmacist Objectives:
1. Explain the importance of starting antiretroviral therapy prior to pregnancy or
early during pregnancy.
2. State the zidovudine dosing for intrapartum women with a HIV RNA > 400
copies/mL.
3. Evaluate the primary literature behind the new guideline recommendations
Technician Objectives:
1. Explain the importance of starting antiretroviral therapy prior to pregnancy or
early during pregnancy.
2. Evaluate the primary literature behind the new guideline recommendations.
3. Distinguish between pregnant patients with a HIV RNA > and < 400 copies/mL.
6
Thursday, April 25th (Continued)
Time
Total
Hours
15:30-16:30
1 hr.
Speaker/Presentation Title
“Pearls – Session II” (Continued)
Matthew Lillyblad, PharmD – “Optimizing Antithrombotic Therapy in Patients with
Concomitant Atrial Fibrillation and Coronary Artery Disease”
Pharmacist Objectives:
1. Describe the risk of stroke and recurrent ischemic events in patients with atrial
fibrillation and coronary artery disease.
2. Compare the bleeding risks of single, dual, and triple antithrombotic therapy.
3. Explain the 2012 CHEST Guidelines for single, dual, and triple antithrombotic
therapy for patients with atrial fibrillation and coronary artery disease at
various risks for stroke and recurrent ischemic events.
Technician Objectives:
1. List commonly used antithrombotic agents for atrial fibrillation and coronary
artery disease
2. Explain why combining antithrombotic agents increases the risk of bleeding
3. Identify patients on single, dual, and triple antithrombotic therapy who may
need an adjustment in their antithrombotic regimen.
17:00-18:00
1 hr.
“Outstanding Resident Research Project Award”
Moderators: Anna Benson, PharmD, BCPS & Jessica Swearingen, BS, PharmD
0134-0000-13-067-L01-P; 0134-0000-13-067-L01-T
David Gurda, PharmD, PGY-1 Pharmacy Practice Resident - United Hospital (Allina
Health)
“A Comparison of Lidocaine, Buffered Lidocaine, and Bacteriostatic Normal Saline for Local
Anesthesia Prior to Peripheral Intravenous Catheterization”
Jordan Haag, PharmD, PGY-2 Pharmacotherapy Specialty Resident – Mayo Clinic
“Drug Related Problems in the Emergency Department: Prospective Validation and
Refinement of a Real-Time Electronic Surveillance and Notification System”
Daniel Wojenski, PharmD, BCPS, PGY-2 Hematology/Oncology Resident – Mayo
Clinic
“Comparison of Toxicity, Efficacy, and Dose Modifications in Obese and Non-Obese
Patients Receiving Modified FOLFOX6 for Metastatic Colorectal Cancer”
Pharmacist Objectives:
1. Describe study methodology and/or interventions utilized to attain predefined
outcomes.
2. Interpret data or information collected to summarize project results.
3. Utilize study results to demonstrate the impact of residency research on
advancing pharmacy practice and attaining health-system and/or pharmacy
department goals.
4. Identify study limitations, steps for implementing research into practice and
implications for future research.
5. Describe how the study results will impact patient care.
Technician Objectives:
1. Describe the relationship between outcomes studied and influence on
technician work.
2. Summarize how the project results may impact pharmacy practice.
3. Demonstrate how residency research can advance pharmacy practice.
4. If applicable, identify future research opportunities related to advancing
technician practice.
7
Total Hours:
Friday, April 26th
Time
11.5 hours (7 obtainable hours) – April 25th Thursday
Total
Hours
Speaker/Presentation Title
KEYNOTE SESSION
08:30 - 09:30 1 hr.
Kim McCoy, MPH, MS; Todd Lemke, PharmD, CDE; Molly Ekstrand, RPh, AE-C, CDE
“Covering the Health System Bases for Patient Safety”
0134-0000-13-068-L05-P; 0134-0000-13-068-L05-T
Pharmacist Learning Objectives:
1. Describe how pharmacy services can help to optimize patient safety and reduce
costs through care coordination across settings and disciplines
2. Identify opportunities to integrate pharmacists and medication management
into patient care
3. Demonstrate how pharmacists can make the most of ongoing Minnesota
initiatives to increase access to clinical pharmacy services
4. Challenge pharmacists and other providers to apply a population health
approach to patient safety and quality of care
5. Issue a call to action to pharmacists to strengthen medication management
through advocacy, innovation and implementation of evidence-based practices
Technician Program Learning Objectives:
1. Describe how pharmacy services can help to optimize patient safety and reduce
costs through care coordination across settings and disciplines
2. Identify opportunities to integrate pharmacists and medication management
into patient care
3. Demonstrate how pharmacists can make the most of ongoing Minnesota
initiatives to increase access to clinical pharmacy services
4. Challenge pharmacists and other providers to apply a population health
approach to patient safety and quality of care
5. Issue a call to action to pharmacists to strengthen medication management
through advocacy, innovation and implementation of evidence-based practices
9:45 -10:45
1 hr.
Bradley A. Boucher, PharmD, FCCP, FCCM, BCPS - “Achieving Hemostasis in Operating
Room the Critical Care Setting: What the Pharmacist Needs to Know”
0204-0000-13-416-L01-P
****”Program accredited through ASHP Advantage” ****
Attendees must complete a continuing Pharmacy Education Request online and
may print their official ASHP statements of continuing pharmacy education
credit at the ASHP eLearning site (http://elearning.ashp.org) immediately
following this activity.
Learning Objectives:
1. Discuss the clinical and economic impact of surgical complications that result in
bleeding and transfusion.
2. Demonstrate knowledge of local and systemic hemostatic agents, including
clinical, safety, economic, and regulatory factors.
3. Describe the role of the health-system pharmacist in the use of hemostatic
agents to manage surgical bleeding.
9:45 -10:45
No Credit
“Pharmacy Practice Act (Roundtable)”
8
Moderator: Shane Madsen, PharmD, BCPS
Friday, April 26th (continued)
Time
9:45–10:45
Total
Hours
1 hr.
Speaker/Presentation Title
Christina Glasgow, PharmD, BCPS – “Medication Considerations for Pharmacists Caring
for Post Bariatric Surgery Patients”
Sampaguita Wright, PharmD – “Tips for Pharmacists Caring for Patients with Ventricular
Assist Devices”
0134-0000-13-070-L04-P; 0134-0000-13-070-L04-T
Pharmacist Learning Objectives:
(Christina Glasgow)
1. Differentiate the bariatric surgeries available in the United States.
2. Describe the potential impact of each bariatric procedure on medication
absorption and therapeutic outcomes.
3. Identify strategies for overcoming decreased medication absorption and
improving therapeutic outcomes.
(Sampaguita Wright)
1. Describe the physiology of left ventricular assist devices (LVADs) and discuss
how these devices benefit patients with advanced heart failure.
2. Evaluate overall treatment goals for patients with LVADs.
3. Discuss medications and medication classes commonly prescribed to patients
with LVADs.
4. Discuss potential complications that may occur after LVAD implantation.
5. Determine appropriate medication changes and schedule follow-up labs for a
patient with an LVAD, based on patient characteristics and hemodynamics.
Technician Learning Objectives:
(Christina Glasgow)
1. Describe the different types of bariatric surgeries available in the United
States
2. Explain why different medication formulations are necessary for post bariatric
surgery patients
3. Identify ways to modify different medication formulations to improve
medication absorption.
(Sampaguita Wright)
1. Identify LVADs currently available for bridge to transplant (BTT) and
destination therapy (DT) in the United States
2. Describe common medications prescribed to patients with LVADs.
3. List potential complications that may occur after LVAD implantation.
10:45-11:45
1hr
Julie Cunningham, PharmD, BCPP – “Opioid Discontinuation: The Art of Tapering
Opioids”
0134-0000-13-071-L01-P, 0134-0000-13-071-L01-T
Pharmacist Learning Objectives:
1. Discuss current literature evidence for safe tapering of opioids in patients with
chronic use.
2. Review opioid withdrawal symptoms and factors that may contribute to the
intensity of symptoms.
3. Describe relevant pharmacokinetic information that impacts the development
of opioid tapers.
4. Discuss concurrent medications, disease states that may require opioid taper
adjustments.
9
5. Review case examples and develop plans to taper opioids.
Friday, April 26th (continued)
Time
10:45-11:45
Total
Hours
1hr
Speaker/Presentation Title
Julie Cunningham (Continued)
Technician Learning Objectives:
1. Review opioid withdrawal symptoms
2. Describe relevant medication issues that impact the rate of opioid taper.
3. Discuss concurrent medications, disease states that may require opioid taper
adjustments.
4. Review case examples and develop plans to taper opioids.
10:45-11:45
1 hr.
Michael Botorff, PharmD, FCCP, FNLA, CLS – “Essential Guidelines for Hospital
Pharmacists in Acute Coronary Syndrome”
0468-000-13-002-L01-P
****Program accredited through Medical Learning Institute****
Learning Objectives:
1. Discuss current updates on treatment guidelines for ACS.
2. Review recent advances in treatment, technology/techniques to improve
ventricular function and relieve symptoms.
3. Describe the value and need for adherence to treatment guidelines and provide
evidence-based solutions to treatment with current therapies.
4. Examine through different cas scenarios the current treatment
options/techniques utilized to address ACS.
10:45-11:45
1hr.
James M. Hoffman, PharmD, M.S., BCPS - “Preparing Your Practice for Biosimilars”
0204-0000-13-415-L01-P
****Program accredited through ASHP Advantage****
Attendees must complete a Continuing Pharmacy Education Request online and
may print their official ASHP statements of continuing pharmacy education
credit at the ASHP eLearning site (http://elearning.ashp.org) immediately
following this activity.
Learning Objectives:
1. Review the intricate scientific process used to produce biopharmaceutical
agents and compare it with the process used to create traditional chemical
drug products.
2. Examine potential approaches to monitoring and identifying unique adverse
events that could emerge with biosimilars.
3. Review key information that will be needed to evaluate biosimilars for
formulary consideration.
4. Develop a plan for the introduction of biosimilars into routine health-system
practice, including an approach to transitions of care.
12:00 – 12:15 No Credit
Kathryn Schultz, PharmD, FASHP – “Navigating the ASHP Summer Meeting”
10
Friday, April 26th (continued)
Time
Total
Hours
Speaker/Presentation Title
KEYNOTE SESSION:
12:15-13:15
1 hr.
Paul W. Abramowitz, PharmD, FASHP, Chief Executive Officer of American Society of
Health-System Pharmacists (ASHP) – “Transforming Patient Care: Paramount Issues and
Opportunities in Pharmacy Practice”
0134-0000-13-069-L04-P; 0134-0000-13-069-L04-T
Pharmacist Learning Objectives:
1. Discuss future pharmacy practice models, and new methods of care delivery to
improve care outcomes.
2. Identify strategies to redesign the medication use system in and across sites of
care.
3. Explain future workforce, education, training, credentialing and privileging
requirements necessary for pharmacists, technicians to provide optimal care,
and accreditation for pharmacy practice sites.
4. Describe the importance and process for pharmacists to obtain provider status
as a non-physician provider under Section 1861 of the Social Security Act and
detail Pharmacy’s advocacy efforts.
5. Discuss the Accountable Care Organization Model and how pharmacists should
participate.
6. Identify opportunities and ways pharmacists can educate the public, patients,
and public payers in order to further advance the profession.
7. Summarize the vital role pharmacists play as primary care providers, describe
their contribution to the advancement of complete and integrated care, and
outline the tools needed to achieve this outcome.
Technician Learning Objectives:
1. Discuss future pharmacy practice models, and new methods of care delivery to
improve care outcomes.
2. Identify strategies to redesign the medication use system in and across sites of
care.
3. Explain future workforce, education, training, credentialing and privileging
requirements necessary for pharmacists, technicians to provide optimal care,
and accreditation for pharmacy practice sites.
Total Hours:
7 hours (4 obtainable hours) – April 26, 2013
GRAND TOTAL:
18.5 Program Hours (11 obtainable hours) – April 25-26, 2013
11